Navigation Links
CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
Date:6/23/2011

BARCELONA, Spain, June 23, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented pre-clinical research results at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) decrease pancreatic cancer tumor blood flow and reduce blood vessel density in vivo.  The research was conducted by CureFAKtor scientists at the Roswell Park Cancer Institute in Buffalo, New York.

In a poster presentation, CureFAKtor Senior Scientist Dr. Elena Kurenova reported the antiangiogenic effect of the Company's lead small molecule compound, CFAK-C4, in pancreatic cancer tumors. Contrast-enhanced magnetic resonance imaging (MRI) revealed significant reduction in tumor vascular volume and permeability in CFAK-C4-treated pancreatic tumors in vivo.  MRI-based changes in tumor vascularity were seen at both the first and second week after therapy.

CureFAKtor scientists analyzed the blood vessel density in a subcutaneous mouse pancreatic tumor model in two CFAK-C4 treated groups and compared vessel density to control group tumors treated with phosphate-buffered saline (PBS). One group was treated for 35 days with treatment starting the day after cell injection.  The second treatment group started when tumors reached a volume of 100 cubic millimeters (mm). Tumors from both groups demonstrated statistically significant reduction of blood vessels per square mm equaling blood vessel density.

A CureFAKtor study reported earlier this year pinpointed the site of interaction of VEGFR-3 and FAK to create small molecule drugs capable of disrupting signaling and causing death of pancreatic cancer cells.  CFAK-C4, reduced tumor growth in vivo in mouse pancreatic cancer cells by up to 60 percent, and CFAK-C4 combined with chemotherapy drug gemcitabine had a synergistic effect and led to 80 percent pancreatic cancer tumor reduction.  

The study also found that CFAK-C4 combined with gemcitabine had a prolonged effect on pancreatic tumor growth.  Two weeks after treatment, the tumor size in the previously treated group was approximately 75 percent smaller than the tumor in the control group. The researchers concluded that targeting FAK with small molecule inhibitors can be effectively used to develop potential oral-based cancer therapies.

"We continue to gain knowledge about the activity of our lead compound, CFAK-C4, and this most recent study furthers our understanding of FAK inhibitors and the potential of this compound," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals.  "CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumor cancers in that its unique mechanism of action disrupts the signaling of specific protein to protein binding between FAK and tumors."

Earlier this year, CureFAKtor received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options.

About Focal Adhesion Kinase (FAK)

Focal adhesion Kinase (FAK) is substantially over-expressed in many solid tumors. FAK operates by placing itself at the contact points between tumor cells and the extra cellular matrix that surrounds them. Studies by CureFAKtor and others found that in this role, FAK is an important facilitator for signals that cause tumor cells to survive, grow, and produce new blood vessels to sustain growth and travel to distant places within the body where they may establish new tumor sites. It also cocoons the tumor cells to protect them from the body's natural signaling mechanisms that would cause deviant tumor cells to be eliminated. In a similar fashion, FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies.  

About CureFAKtor Pharmaceuticals

CureFAKtor Pharmaceuticals is a biopharmaceutical company focused on the research and development of Focal Adhesion Kinase therapies to prevent or treat cancer.  The Company has identified more  than 40 compounds that target specific FAK signaling sites.  CureFAKtor's investigational and combination therapy products target pancreatic, breast, colon, melanoma, lung and brain oncology disorders. CureFAKtor research is conducted at the Roswell Park Cancer Institute.  CureFAKtor is planning a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy, the current standard of care for pancreatic cancer, in 2012.  Additional information about the company may be found at www.curefaktor.com

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for CureFAKtor Pharmaceuticals that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements.  

Media Contact
Rx Communications Group, LLC
Eric Goldman
Vice President, Public Relations
917-322-2563
egoldman@rxir.com


'/>"/>
SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
2. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
3. MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
4. Radient Pharmaceuticals Corporation Joins OTCQX
5. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
6. Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
7. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
8. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
9. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
10. Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
11. Cubist Pharmaceuticals Applauds Congressman Gingrey for Introducing Legislation to Help Fight Superbug Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... ... 24, 2017 , ... Ridgecrest Herbals makes it a point to lead the ... waste, and support renewable energy. They believe this is a crucial part of their ... for health issues, and maintain that destroying the environment in the pursuit of profit ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, ... inhabiting the rarified air of pop and film stardom.(1) Not to be left out ... the smile. Grins now run the gamut from being encrusted with jewels and precious ...
(Date:4/24/2017)... Washington (PRWEB) , ... April 24, 2017 , ... Sean ... OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which ... perhaps any other marketer in the last 25 years. , Now, due to changes ...
Breaking Medicine News(10 mins):